https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-08 17:22:332026-04-08 17:22:56Hansa Biopharma to host Q1 2026 interim results conference call
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-08 17:22:332026-04-08 17:22:56Hansa Biopharma to host Q1 2026 interim results conference call
https://www.optimumcomms.com/wp-content/uploads/2026/04/SonoNeu_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-07 08:07:032026-04-07 08:07:03SonoNeu exits stealth as key part of US Government-funded research program worth up to $41.3m to advance sonogenetics into clinic
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-31 08:33:582026-03-31 08:33:58Grant of first POLB 001 cancer immunotherapy-induced CRS patent
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-26 08:34:052026-03-26 08:34:05Hansa Biopharma publishes 2025 Annual and Sustainability Reports
https://www.optimumcomms.com/wp-content/uploads/2026/02/Laigo-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-23 08:50:032026-03-23 08:50:03Laigo Bio completes final close of oversubscribed seed financing of €17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
https://www.optimumcomms.com/wp-content/uploads/2025/07/hansa.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-20 09:13:472026-03-20 09:13:47Hansa Biopharma announces a USD 30 million convertible note financing
https://www.optimumcomms.com/wp-content/uploads/2026/02/BOOSTPharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-19 11:30:522026-04-01 12:29:59BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-19 08:38:462026-03-19 08:38:46Oncoinvent secures new patent expanding protection for Radspherin®
https://www.optimumcomms.com/wp-content/uploads/2026/01/Atrogi_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-18 08:34:592026-03-18 08:34:59Atrogi announces first subjects dosed in human trial for lead candidate ATR-258
https://www.optimumcomms.com/wp-content/uploads/2026/03/AMS_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-18 07:10:522026-03-18 07:10:52Advanced Medical Solutions Group plc: Unaudited preliminary results for the year ended 31 December 2025
https://www.optimumcomms.com/wp-content/uploads/2026/03/R1_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-17 12:28:512026-03-17 12:28:51R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
https://www.optimumcomms.com/wp-content/uploads/2024/04/Outrun_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-17 08:35:202026-03-17 08:35:20Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)
https://www.optimumcomms.com/wp-content/uploads/2026/03/Mestag_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-17 08:17:292026-03-17 08:17:29Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-13 16:34:222026-03-13 16:34:22Hansa Biopharma presenting at Redeye Theme Event: Commercialization in Life Science
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-12 08:34:542026-03-12 08:35:12Poolbeg Pharma plc – Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-12 08:28:432026-03-12 08:28:58Novo Holdings announces 2025 Annual Results We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
